Henry Mendoza, MD
Internal Medicine · Flint, MINPI 1255426102
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Sunovion Pharmaceuticals Inc. accounts for 61.2% of it on its own, with 52 other manufacturers making up the rest. Reporting peaked in 2019 at $19,263 and has fallen 92.1% since, to $1,520 in 2025. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 522 payments — averaging $54.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$18K
- Amgen$2K
- AbbVie$1K
- AstraZeneca$857
- Grifols USA, LLC$626
- Bayer$608
- plus $6K from 47 others
Across 6 payments — averaging $24,416 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$146K
What the payments were for
- Speaking & faculty fees$14,84052%
- Travel & lodging$1,6616%
- Food & beverage$12,03842%
- Education$1330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,673 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 156 | $144,515 |
| TrulicityDulaglutide | 35 | $50,203 |
| OzempicSemaglutide | 43 | $45,992 |
| XareltoRivaroxaban | 39 | $36,288 |
| JardianceEmpagliflozin | 26 | $35,972 |
| XifaxanRifaximin | 13 | $34,947 |
| EntrestoSacubitril/Valsartan | 28 | $34,412 |
| RexultiBrexpiprazole | 11 | $29,067 |
| JanuviaSitagliptin Phosphate | 27 | $28,967 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $28,717 |
| GemtesaVibegron | 30 | $20,439 |
| Victoza 3-PakLiraglutide | 13 | $20,133 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $15,187 |
| BrilintaTicagrelor | 23 | $13,023 |
| TradjentaLinagliptin | 13 | $10,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin, Paxlovid | $159 | $158,439189 claims |
| Lilly USA, LLCTrulicity | $322 | $50,20335 claims |
| Novo NordiskOzempic | $551 | $45,99243 claims |
| Johnson & JohnsonXarelto | $150 | $36,28839 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $516 | $34,94713 claims |
| NovartisEntresto | $31 | $34,41228 claims |
| MerckJanuvia, Belsomra | $45 | $33,92539 claims |
| AstraZenecaBreztri Aerosphere, Brilinta, Symbicort | $857 | $32,22056 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $185 | $29,06711 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $296 | $20,43930 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $66 | $14,46932 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $73 | $10,59015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Flint
- Sajjad GulFlint$39K
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
- Mohamad HatahetWaterford$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.